Author

Alessandro Armuzzi 1

1 IBD Unit,Complesso Integrato Columbus, Catholic University,R

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Fernando Gomollon Garcia, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James Lindsay, Laurent Peyrin-Biroulet, Garret Cullen, Marco Daperno, Torsten Kucharzik, Florian Rieder, Sven Almer, Alessandro Armuzzi, Marcus Harbord, Jost Langhorst, Miquel Sans, Yehuda Chowers, Gionata Fiorino, Pascal Juillerat, Geras

A MULTINATIONAL STUDY TO DETERMINE INDICATORS OF SUBOPTIMAL THERAPY AMONG ULCERATIVE COLITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ANTAGONISTS

James Lindsay, Javier Gisbert, Reema Mody, Laurent Peyrin-Biroulet, Alessandro Armuzzi, Bernd Bokemeyer, Geoffrey C. Nguyen, Jean Siebenaler, Örjan Åkerborg, Michael Smyth

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED ALPHA4BETA7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDEAL STUDY

Scott Plevy, Bruce E. Sands, Julian Panés, Geert R. D'Haens, Vipul Jairath, Brian G. Feagan, Suneel Gupta, C. C. Hwang, Scott Lee, Alessandro Armuzzi, Walter Reinisch, Stefan Schreiber, William J. Sandborn

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Laurent Peyrin-Biroulet, Alessandro Armuzzi, Raja Atreya, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charlie Lees, Edouard Louis, Milan Lukas, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

Amgen - The emerging treatment landscape of IBD: role of innovator biologics and biosimilars (Amgen Europe GmbH)

Alessandro Armuzzi, Jean-Frederic Colombel, Walter Reinisch

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Alessandro Armuzzi, Christina Ha, Michael Chiorean, Nervin Lawendy, Rajiv Mundayat, Leonardo Salese, John C. Woolcott, Chinyu Su, Iris Dotan

Anti-TNF to prevent and treat postoperative recurrence of Crohn's disease

Alessandro Armuzzi

Are we choosing wisely in inflammatory bowel disease care? The IG-IBD choosing wisely campaign

Marco Vincenzo Lenti, Alessandro Armuzzi, Fabiana Castiglione, Massimo Claudio Fantini, Gionata Fiorino, Ambrogio Orlando, Daniela Pugliese, Fernando Rizzello, Maurizio Vecchi, Antonio Di Sabatino

ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS.

Luisa Guidi, Manuela Marzo, Carla Felice, Daniela Pugliese, Gianluca Andrisani, Giammarco Mocci, Olga Maria Nardone, Gian Lodovico Rapaccini, Alfredo Papa, Alessandro Armuzzi, Gian Lodovico Rapaccini

Item 1 - 10 / 108
1
2 3 4 5 6 7
...
10 11